Loading patent…
AssigneeOxular Limited
InventorsPeter Charlton, Afsoon Fallahi, Tien Nguyen, Ronald Yamamoto
Estimating the term…
The present invention provides a method for the treatment of retinoblastoma comprising administering a composition comprising a therapeutically active agent to a subject in need thereof by injection of the composition into the vitreous cavity, suprachoroidal space, supraciliary space or sub-Tenon's space of the eye adjacent to a retinoblastoma tumour. The invention also provides a composition comprising at least one therapeutically active agent selected from the group consisting of a Bcl-2 inhibitor or a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the composition is for administration into the vitreous cavity, suprachoroidal space, sub-Tenon's space, or supraciliary space adjacent to a retinoblastoma tumour in an eye. Also provided is a kit comprising a Bcl-2 inhibitor and a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the Bcl-2 inhibitor and the topoisomerase inhibitor are for separate, simultaneous or sequential administration. The invention also provides a kit comprising a composition comprising at least one therapeutically active agent and a cannulation or catheterization device for use in the treatment of retinoblastoma.
A method for the treatment of retinoblastoma comprising administering a composition comprising a therapeutically active agent to a subject in need thereof by injection of the composition into the vitreous cavity, suprachoroidal space, supraciliary space or sub-Tenon's space of the eye adjacent to a retinoblastoma tumour.
A composition comprising at least one therapeutically active agent selected from the group consisting of a Bcl-2 inhibitor, a HDAC inhibitor or a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the composition is for administration into the vitreous cavity, suprachoroidal space, sub-Tenon's space, or supraciliary space adjacent to a retinoblastoma tumour in an eye.
A kit comprising a Bcl-2 inhibitor, a HDAC inhibitor and/or a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the Bcl-2 inhibitor and the topoisomerase inhibitor are for separate, simultaneous or sequential administration.
The use of a Bcl-2 inhibitor, a HDAC inhibitor or a topoisomerase inhibitor in the manufacture of a medicament for the treatment of retinoblastoma by administration into the vitreous cavity, suprachoroidal space or sub-Tenon's space adjacent to a retinoblastoma tumour in an eye.
A kit comprising a composition comprising at least one therapeutically active agent and a cannulation or catheterization device for use in the treatment of retinoblastoma in an eye, wherein the at least one therapeutically active agent is selected from the group consisting of a Bcl-2 inhibitor, a HDAC inhibitor or a topoisomerase inhibitor and wherein the cannulation or catheterization device is configured for delivery of the composition to the suprachoroidal space or supraciliary space.
Dependencies are inferred from the claim text.